What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM).
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Carnero Contentti Edgar, Lopez Pablo A, Pettinicchi Juan Pablo, Pappolla Agustín, Miguez Jimena, Patrucco Liliana, Cristiano Edgardo, Vrech Carlos, Tkachuk Verónica, Liwacki Susana, Correale Jorge, Marrodan Mariano, Gaitán María I, Fiol Marcela, Negrotto Laura, Ysrraelit María C, Burgos Marcos, Leguizamon Felisa, Tavolini Dario, Deri Norma, Balbuena Maria E, Mainella Carolina, Luetic Geraldine, Blaya Patricio, Hryb Javier, Menichini María L, Alvez Pinheiro Amelia, Nofal Pedro, Zanga Gisela, Barboza Andrés, Martos Ivan, Lazaro Luciana, Alonso Ricardo, Silva Emanuel, Bestoso Santiago, Fracaro Maria E, Carrá Adriana, Garcea Orlando, Fernandez Liguori Nora, Alonso Serena Marina, Caride Alejandro, Rojas Juan I
Аннотация
METHODS: RelevarEM is a longitudinal, strictly observational multiple sclerosis (MS) and NMOSD registry in Argentina. Of 3031 consecutive patients (until March 2020), 165 patients with phenotype of suspected NMOSD, whose relevant data for the purpose of this study were available, were included. Data on demographic, clinical, paraclinical and treatment in AQP4-ab (positive, negative and unknown) and MOG-ab (positive and negative) patients were evaluated.
RESULTS: A total of 165 patients (79 AQP4-Ab positive, 67 AQP4-Ab negative and 19 unknown) were included. Of these, 155 patients fulfilled the 2015 NMOSD diagnostic criteria. Of 67 AQP4-Ab-negative patients, 36 (53.7%) were tested for MOG-Ab and 10 of them (27.7%) tested positive. Serum AQP4-ab levels were tested by means of cell-based assay (CBA) in 48 (35.2%), based on tissue-based indirect immunofluorescence assays in 58 (42.6%) and enzyme-linked immunosorbent assay in 4 (2.9%). All MOG-ab were tested by CBA. Optic neuritis (90%) was the most frequent symptom at presentation and optic nerve lesions the most frequent finding (80%) in neuroimaging of MOG-ab-associated disease. Of these, six (60%) patients were under immunosuppressant treatments at latest follow-up.
CONCLUSION: We observed that 27.7% (10/36) of the AQP4-ab-negative patients tested for MOG-ab were positive for this antibody, in line with results from other world regions.